Biotech
News Category
VERAXA Biotech Shareholders Overwhelmingly Approve Governance and Financing Measures
VERAXA Biotech AG shareholders approved key governance changes and financing flexibility with over 99.94% support, enabling the company to pursue grow...
VERAXA Biotech Advances Bispecific ADC Program with OmniAb, Targeting Solid Tumors with Precision 'AND-Gate' Approach
VERAXA Biotech AG (NASDAQ: VRXA) has advanced its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, leveraging...
Gerresheimer Doubles Injectable Packaging Capacity in China with New Zhenjiang Dagang Plant
Gerresheimer has started operations at a new plant in Zhenjiang Dagang, China, doubling its production capacity for primary packaging for injectable p...
Darwin AG Rebrands as Novogenia AG to Unify Corporate and Brand Identity
Darwin AG has changed its name to Novogenia AG to align its corporate identity with its core operating brand, strengthening its international presence...
NanoViricides Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC
NanoViricides progresses NV-387, a broad-spectrum oral antiviral, toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, where no ...
Redwood AI Corp. Added to CSE25 Index, Boosting Visibility Among Investors
Redwood AI Corp. has been included in the CSE25 Index, reflecting its growth and potential to attract institutional and retail investors interested in...
Helus Pharma Reports Fiscal 2026 Results, Highlights Phase 3 Progress for Major Depressive Disorder Treatment
Helus Pharma announced fiscal 2026 financial results and clinical pipeline updates, emphasizing the Phase 3 APPROACH trial for HLP003 in major depress...
Quantum BioPharma’s Lucid-MS Offers New Hope for Multiple Sclerosis Treatment
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting its novel drug candidate Lucid-MS, which directly targets myelin repair in m...
The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation
Advancements in nanomedicine and drug-delivery systems, such as Oncotelic Therapeutics' Deciparticle platform, are poised to enhance the efficacy of e...
Quantum BioPharma’s Lucid-MS Advances Toward Phase 2 Trials, Offering Potential Paradigm Shift in Multiple Sclerosis Treatment
Quantum BioPharma Ltd. is advancing its novel MS therapy, Lucid-MS, toward Phase 2 trials, which directly protects myelin rather than modulating the i...
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Enhancing Precision Cancer Therapy
VERAXA Biotech announced new in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating tumor-restricted activation and reduced toxicity...
Redwood AI Corp. Leverages AI Platforms to Accelerate Chemistry R&D Across Multiple Sectors
Redwood AI Corp. is highlighted as a company to watch for its AI-powered platforms that aim to accelerate chemistry research and development in pharma...
NanoViricides Receives DRC Approval to Advance Phase II Ebola Trial with Oral Gummies
NanoViricides announced approval from the DRC's Pillar Committee to proceed with a Phase II trial for NV-387 Oral Gummies against the Bundibugyo ebola...
Helus Pharma Chief Medical Officer to Present at H.C. Wainwright Neuro Perspectives Conference
Helus Pharma announces its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright conference, highlighting the company's pro...
Onco-Innovations Advances ONC010 Manufacturing Process Development
Onco-Innovations Limited announced the initiation of process development and scale-up for its drug candidate ONC010, a key step toward IND-enabling st...
Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis After Positive Phase 1 Results
Quantum BioPharma reported favorable safety data from Phase 1 trials of LUCID-MS, a novel therapy aimed at protecting myelin and addressing neurodegen...
NeuroOne to Present at Planet MicroCap Las Vegas 2026 Conference
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference, providing commercialization updates and milestones for it...
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
GeoVax CEO David Dodd comments on recent pharmaceutical acquisitions that signal a strategic shift toward prioritizing vaccine innovation, health secu...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities on BioMedWire Podcast
Quantum BioPharma's co-founder discusses the potential of Lucid-MS for multiple sclerosis and the commercial success of unbuzzd, with an upcoming Phas...
Helus Pharma to Participate in Jefferies Global Healthcare Conference
Helus Pharma announces its participation in the Jefferies Global Healthcare Conference, highlighting its clinical-stage development of novel serotoner...
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
TransCode Therapeutics has started a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurre...
NanoViricides Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak
NanoViricides announces that its broad-spectrum antiviral candidate NV-387 may be evaluated for the Bundibugyo Ebola outbreak, citing its host-targete...
SureNano Science Ltd. Positions Itself in GLP-1 Obesity Drug Market with Novel Peptide GEP-44
SureNano Science Ltd. is advancing GEP-44, a patented GLP-1 peptide targeting obesity and metabolic disorders, aiming to compete with blockbuster drug...
Oncotelic Therapeutics Integrates 28 Million Scientific Abstracts into AI Platform, Signaling Shift in Drug Discovery
Oncotelic Therapeutics has integrated 28 million scientific abstracts into its PDAOAI platform, positioning itself as a key player in the AI-driven dr...
Telomir Pharmaceuticals Reports Peer-Reviewed Preclinical Data Supporting Telomir-Zn in Wilson's Disease
Telomir Pharmaceuticals announced publication of peer-reviewed preclinical data showing Telomir-Zn improves survival and reduces oxidative stress and ...
Lantern Pharma Receives FDA Support for HARMONIC Trial Amendments in Never-Smoker NSCLC
Lantern Pharma announced FDA clearance for protocol amendments to its Phase 2 HARMONIC trial, focusing LP-300 on EGFR-mutant never-smokers with advanc...
NanoViricides Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak
NanoViricides emphasizes the potential of its oral drug candidate NV-387 for treating Ebola and other filoviruses, positioning it as a key pandemic pr...
Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study, Preliminary Data Show Promise
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached midpoint enrollmen...
LIXTE Biotechnology Reports First-Quarter Progress on Oncology Pipeline and Strategic Expansion
LIXTE Biotechnology Holdings announced first-quarter 2026 progress including expansion of its ovarian cancer trial for lead candidate LB-100 and conti...
Dogwood Therapeutics Reports First Quarter 2026 Results, Eyes Key Data for Halneuron and SP16
Dogwood Therapeutics announced first quarter 2026 financial results with pipeline progress including Phase 2b data for Halneuron expected in fall 2026...
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Innovations in crossing the blood-brain barrier, such as Oncotelic's intranasal nose-to-brain delivery system, are poised to transform CNS treatment a...
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
Hantavirus Fatalities on Cruise Ship Highlight Risks and Need for Diagnostic Advances
The outbreak of hantavirus on the MV Hondius cruise ship, resulting in three fatalities, underscores the dangers of this rare infection and the import...
NanoViricides Receives Orphan Drug Designation for NV-387 as Measles Treatment
NanoViricides' NV-387, a broad-spectrum antiviral, has been granted Orphan Drug Designation by the FDA for measles, offering incentives and supporting...
VolitionRx Reports Finger-Prick Breakthrough for Nucleosome Detection in Sepsis
VolitionRx announces a technical milestone in detecting nucleosomes in capillary blood from sepsis patients using a lateral flow finger-prick prototyp...
Helus Pharma Partners With TARA Mind to Enhance Phase 3 Trial Recruitment for Major Depressive Disorder Treatment
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 PARADIGM trial of HLP003, a Breakthrough Therapy-designated trea...
Ventripoint's VMS+ 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.
Ventripoint Diagnostics Ltd. announces that its strategic partner Lishman Global Inc. has submitted the VMS+ 4.0 system for NMPA approval in China, wi...
Formycon AG to Present FY2025 Results and Participate in Q2 2026 Investor Conferences
Formycon AG will publish its fiscal year 2025 results on April 22, 2026, host a conference call, and participate in several international investor con...
Helus Pharma Appoints Dr. Ken Kramer as SVP of Medical Affairs to Advance Serotonergic Agonist Pipeline
Helus Pharma announced the appointment of Dr. Ken Kramer as senior vice president of medical affairs, bringing over 20 years of neuroscience medical a...
GeoVax Reports 2025 Year-End Financial Results and Prepares for Pivotal Phase 3 Trial of GEO-MVA Mpox/Smallpox Vaccine
GeoVax Labs announced its 2025 financial results and business update, highlighting plans to initiate a pivotal Phase 3 trial for its GEO-MVA vaccine i...
Kairos Pharma Earns 2026 Pinnacle Award for Biotech Innovation in Cancer Drug Resistance
Kairos Pharma's recognition with the 2026 Pinnacle Award highlights its pioneering work in targeting cancer drug resistance through its lead candidate...
HeartBeam Initiates Public Offering to Fund Commercialization and AI Development
HeartBeam launched an underwritten public offering to raise capital for commercializing its FDA-cleared 12-lead synthesized ECG system, advancing hear...
Lixte Biotech Advances Precision Oncology Strategy With LB-100, Expands Clinical Trials and Partnerships
Lixte Biotechnology is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance existing cancer treatments, through expanded ...
Lixte Biotechnology Advances Precision Oncology with LB-100, Expands Clinical and Strategic Partnerships
Lixte Biotech Holdings Inc. is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance existing cancer treatments, while exp...
NanoViricides to Initiate Phase II MPox Trial in DRC, Advancing NV-387 Against Clade I Virus
NanoViricides is set to begin a Phase II trial of its antiviral NV-387 for MPox in the Democratic Republic of Congo, targeting the more severe Clade I...
BioStem Technologies to Present at Needham Virtual Healthcare Conference, Highlighting Regenerative Medicine Innovations
BioStem Technologies will present at the 25th Annual Needham Virtual Healthcare Conference, underscoring its leadership in perinatal tissue allografts...
Telomir Pharmaceuticals Submits IND for Triple-Negative Breast Cancer Candidate Telomir-1
Telomir Pharmaceuticals has submitted an Investigational New Drug application to the FDA for Telomir-1, a novel oral therapy for advanced and metastat...
Ketryx Launches Validated AI Conference for Professionals in Regulated Industries
Ketryx announces the first Validated AI Conference, a new event for engineers and regulatory leaders building AI systems in regulated environments, to...